Patients with advanced kidney cancer in the UK now have access to nivolumab through an early access scheme.
Patients with advanced renal cell carcinoma (RCC)—the 8th most common cancer in the UK—will now have access to nivolumab ahead of a licensing decision in Europe. UK’s Medicines and Healthcare Regulatory Products Agency announced the inclusion of nivolumab in the Early Access to Medicines Scheme, which lends patients access to drugs before they are officially approved.
Patients with RCC usually present with advanced disease when first diagnosed (27% in the UK), of which just 15% of men and 10% of women will survive for 5 years or more; this presents a huge unmet need in the population.
The international phase 3 trial of nivolumab in patients with RCC, Checkmate-025, recruited patients from across 24 countries. The trial was stopped early based on advice from an independent Data Monitoring Committee following results from the phase 3 study—a significant increase in median overall survival of 5.4 months was observed in previously-treated patients with RCC who were administered nivolumab, compared with those treated with everolimus
Nivolumab was only recently approved by the FDA for treating patients with advanced RCC who had progressed on prior therapy. When announcing the approval, Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research said, “Opdivo’s extended indication, from melanoma and non-small cell lung cancer to renal cell cancer, demonstrates how immune therapies can benefit patients across a wide range of tumors.”
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More